Efficacy and tolerability of combination therapy with valsartan/hydrochlorothiazide in the initial treatment of severe hypertension

Current Medical Research and Opinion

Volumn 24, Issue 8, 2008, Pages 2303-2311

  Calhoun, David A ^a   Glazer, Robert D ^b   Pettyjohn, Frank S ^c   Coenen, P D M ^d   Zhao, Yanxing ^b   Grosso, Amie ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF SOUTH ALABAMA   (United States)

^d Huisartsenpraktijk Beek en Donk ^*  (Netherlands)

Author keywords

Blood pressure control; Combination therapy; Hydrochlorothiazide; Severe hypertension; Valsartan

Indexed keywords

HYDROCHLOROTHIAZIDE; PLACEBO; VALSARTAN;

ABNORMAL LABORATORY RESULT; ADULT; AGED; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESSENTIAL HYPERTENSION; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPOTENSION; MALE; MONOTHERAPY; MORNING DOSAGE; MULTICENTER STUDY; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SYNCOPE; SYSTOLIC BLOOD PRESSURE; UPPER RESPIRATORY TRACT INFECTION; UREA NITROGEN BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; DIURETICS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; TETRAZOLES; TREATMENT OUTCOME; VALINE;

EID: 50149117207     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990802271946     Document Type: Review

References (24)

1. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365:217-23
2. Ong KL, Cheung BMY, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007;49:69-75
3. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004;43:10-7
4. Chobanian AV, Bakris GL, Black HR, et al.; and the National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52
5. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13
6. Cook NR, Cohen J, Hebert PR, et al. Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med 1995;155:701-9
7. Cushman WC, Ford CE, Cutler JA, et al.; for the ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich) 2002;4:393-404
8. Julius S, Kjeldsen SE, Weber M, et al.; for the VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31
9. Staessen JA, Thijs L, Fagard R, et al.; for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J Hypertens 2004;22:847-57
10. Weber MA, Julius S, Kieldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet 2004; 363:2049-51
11. Dahlöf B, Sever PS, Poulter NR, et al.; for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowing Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906
12. Caro JJ, Speckman JL, Salas M, et al. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. Can Med Assoc J 1999;160:41-6
13. Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 guidelines for the management of arterial hypertension. J Hypertens 2007; 25:1105-87
14. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 2002;62:443-62
15. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120:713-9
16. Pool J, Oparil S, Hedner T, et al. Dose-responsive antihypertensive efficacy of valsartan, a new angiotensin II-receptor blocker. Clin Ther 1998;20:1106-14
17. Benz JR, Black HR, Graff A, et al. Valsartan and hydrochlorothiazide in patients with essential hypertension: a multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens 1998; 12:861-6
18. Pool JL, Glazer R, Weinberger M, et al. Comparison of valsartan/ hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults. Clin Ther 2007;29:61-73
19. Weir MR, Crikelair N, Levy D, et al. Evaluation of the dose response with valsartan and valsartan/hydrochlorothiazide in patients with essential hypertension. J Clin Hypertens (Greenwich) 2007;9:103-12
20. Salerno CM, Demopoulos L, Mukherjee R, et al. Combination angiotensin receptor/hydrochlorothiazide as initial therapy in the treatment of patients with severe hypertension. J Clin Hypertens (Greenwich) 2004;6:614-20
21. Neutel JM, Franklin SS, Oparil S, et al. Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension. J Clin Hypertens (Greenwich) 2006;8:850-7
22. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressures averaging 115 through 129 mmHg. J Am Med Assoc 1967; 202:116-22
23. Okonofua EC, Simpson KN, Jesri A, et al. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension 2006;47:345-51
24. Andrade SE, Gurwitz JH, Field TS, et al. Hypertension management: the care gap between clinical guidelines and clinical practice. Am J Manag Care 2004;10:481-6